Zevra Therapeutics Inc (ZVRA) News

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors

CELEBRATION, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the...

Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol

By Denny Jacob Xoma will make a $1 million milestone payment to LadRx following the U.S. Food and Drug Administration's acceptance of Zevra...

Form 8-K - Current report

Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

Arimoclomol NDA has been assigned a PDUFA action date of June 21, 2024 CELEBRATION, Fla., Jan. 08, 2024...

Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer

CELEBRATION, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the...

Zevra Therapeutics Refiles Arimoclomol Application With FDA

By Colin Kellaher Zevra Therapeutics has resubmitted a new drug application seeking U.S. Food and Drug Administration approval of its lead product...

Form 8-K - Current report

Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration

CELEBRATION, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) a rare disease...

Form 8-K - Current report

Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company

Acquisition includes OLPRUVA®, an FDA-approved treatment for urea cycle disorders (UCDs), which propels Zevra...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results

Arimoclomol NDA resubmission remains on track for end of year filing Proposed acquisition of Acer Therapeutics...